TROPiCS-02 Update Confirms Sacituzumab Govitecan Survival Advantage
From ASCO 2023 Annual Meeting:
Progression-free and overall survival in metastatic hormone receptor-positive, HER2- negative patients are better with sacituzumab govitecan than chemotherapy